The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
30
81mg twice a day (162mg total)
NYU Langone Health
New York, New York, United States
Measures of platelet aggregation assessed by Light Transmission Aggregometry (LTA)
Time frame: Baseline, 4 weeks after initiation of aspirin
Change in serum thromboxane
Time frame: Baseline, 4 weeks after initiation of aspirin
Change in complete blood count
Time frame: Baseline, 4 weeks after initiation of aspirin
Change in Mean Platelet Volume (MPV)
Time frame: Baseline, 4 weeks after initiation of aspirin
Change in Platelet Distribution Width (PDW)
Time frame: Baseline, 4 weeks after initiation of aspirin
Change in Plateletcrit (PCT)
Time frame: Baseline, 4 weeks after initiation of aspirin
Change in Life's Essential 8 questionnaire
Life's Essential 8 (LE8) is a cardiovascular health scoring system from the American Heart Association that rates health from 0 to 100 based on diet, activity, smoking, sleep, BMI, cholesterol, blood sugar, and blood pressure. Scores indicate high cardiovascular health, 50-79 is moderate, and below 50 is low. A score of 100 is ideal, while 0 represents the lowest health condition, such as severe, uncontrolled risk factors.
Time frame: Baseline, 4 weeks after initiation of aspirin
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.